Therefore, we further developed the column to remove cells producing TGF-β, i.e., LAP+ cells, because we postulated that the removal of LAP+ cells would be more effective than removal of TGF-β for enhancing anti-tumor acquired immunity. The gene discussed is TGFB1; the disease is neoplasm.